JPRN-UMIN000005809招募中未知
A single-blind and crossover study examining the efficacy of intranasal oxytocin administration for social impairments in subjects with pervasive developmental disorders - Pilot study examining the efficacy of intranasal oxytocin administration for social impairments in subjects with pervasive developmental disorders
Department of Neuropsychiatry, Showa University School of Medicine0 个研究点目标入组 60 人开始时间: 2011年6月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 55years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) History of allergy for oxytocin 2) Cannot enter Magnetic Resonance Scanner 3) History of traumatic brain injury with any known cognitive consequences or loss of consciousness for more than 5 minutes 4) History of substance abuse or addiction 5) Instabilized with psychiatric comorbidity
研究者
相似试验
已完成
不适用
A single-blind cross-over study examining the effects of heated humidification to nasopharynx on snoring and self-reported sleep quality in healthy adultHabitual snoringJPRN-UMIN000025380Second Department of Internal Medicine, Nara Medical University30
已完成
不适用
A single-blind crossover study examining the efficacy of moisturizing the nasal cavity for sleep difficulty with healthy adultSleep difficultyJPRN-UMIN000025298Kao Corporation25
进行中（未招募）
不适用
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension.Subjects With HypercholesterolemiaMedDRA version: 9.1Level: PTClassification code 10058108Term: DyslipidaemiaEUCTR2007-001489-34-EETakeda Global Research & Development Centre (Europe) Ltd660
尚未招募
3 期
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extensiohypercholesterolemiaelevated cholesterol10013317NL-OMON31031Takeda71
进行中（未招募）
不适用
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label ExtensioSubjects With HypercholesterolemiaMedDRA version: 9.1Level: PTClassification code 10058108Term: DyslipidaemiaEUCTR2007-001489-34-LVTakeda Global Research & Development Centre (Europe) Ltd660